Table 1 Correlations between Fat4 expression and clinicopathological characteristics in gastric cancer patients
From: FAT4 functions as a tumour suppressor in gastric cancer by modulating Wnt/β-catenin signalling
FAT4 expression | ||||
|---|---|---|---|---|
Characteristics | Number (%) | Negative | Positive | P -value |
Gender | 0.054 | |||
Male | 120 (75.0) | 96 | 24 | |
Female | 40 (25.0) | 26 | 14 | |
Age (years) | 0.213 | |||
<60 | 87 (54.4) | 63 | 24 | |
⩾60 | 73 (45.6) | 59 | 14 | |
Size (cm) | 0.337 | |||
⩾5 | 74 (46.2) | 59 | 15 | |
<5 | 86 (53.8) | 63 | 23 | |
Differentiation | 0.083 | |||
Well | 4 (2.5) | 4 | 0 | |
Moderately | 54 (33.7) | 35 | 19 | |
Poorly | 62 (38.8) | 50 | 12 | |
Other | 40 (25.0) | 33 | 7 | |
Lauren’s classification | 0.05 | |||
Intestinal | 60 (37.5) | 40 | 20 | |
Diffuse | 94 (58.7) | 76 | 18 | |
Mixed | 6 (3.8) | 6 | 0 | |
TNM stage | 0.098 | |||
I | 17 (10.6) | 10 | 7 | |
II | 67 (41.9) | 48 | 19 | |
III | 63 (39.4) | 53 | 10 | |
IV | 13 (8.1) | 11 | 2 | |
Lymph-node metastasis | 0.000a | |||
Present | 99 (61.9) | 85 | 14 | |
Absent | 61 (38.1) | 37 | 24 | |
Liver metastasis | 0.205 | |||
Present | 5 (3.1) | 5 | 0 | |
Absent | 155 (96.9) | 117 | 38 | |
T grade | 0.229 | |||
T1 | 9 (5.6) | 7 | 2 | |
T2 | 10 (6.2) | 5 | 5 | |
T3 | 92 (57.5) | 73 | 19 | |
T4 | 49 (30.6) | 37 | 12 | |
Survival | 0.017a | |||
Alive | 70 (43.8) | 47 | 23 | |
Dead | 90 (56.2) | 75 | 15 | |
